Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids

Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids

(2015) Ariane Giannattasio et al.   BMC CANCER

Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices

(2015) Marine Peria et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Epidermal Growth Factor Receptor Inhibition Reduces Angiogenesis via Hypoxia-Inducible Factor-1α and Notch1 in Head Neck Squamous Cell Carcinoma

(2015) Wei-Ming Wang et al.   PLoS One

In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas

(2015) Esther de Boer et al.   Scientific Reports

Increased sMICA and TGFβ1levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells

(2015) Stephan Klöß et al.   OncoImmunology

Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy

(2014) Claudia Brehm et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Effect of tumor cells and tumor microenvironment on NK-cell function

(2014) Massimo Vitale et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression

(2014) A. Clayton et al.   JOURNAL OF IMMUNOLOGY

A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis

(2014) Antonino Bruno et al.   JNCI-Journal of the National Cancer Institute

Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection

(2014) Hua Li et al.   MOLECULAR CANCER RESEARCH

ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors

(2014) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention

(2014) Aroa Baragaño Raneros et al.   OncoImmunology

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Immune alterations and immunotherapy prospects in head and neck cancer

(2013) Vincent Varilla et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Biomarkers of drugs targeting HER-family signalling in cancer

(2013) Filippo Montemurro et al.   JOURNAL OF PATHOLOGY

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol

(2013) Ulrike Koehl et al.   Frontiers in Oncology

Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers

(2012) M Stern et al.   BONE MARROW TRANSPLANTATION

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients

(2012) María P. Roberti et al.   BREAST CANCER RESEARCH AND TREATMENT

The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture

(2012) Alexander Hoh et al.   LIVER INTERNATIONAL

Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition

(2011) E. Mamessier et al.   CANCER RESEARCH

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

(2011) S. Platonova et al.   CANCER RESEARCH

Immune Suppression in Head and Neck Cancers: A Review

(2011) Anaëlle Duray et al.   Clinical & Developmental Immunology

Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

(2011) Steve C. Lee et al.   IMMUNOLOGIC RESEARCH

Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin

(2011) Jian-Hong Zuo et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

(2011) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression

(2011) Lucas E. Rossi et al.   JOURNAL OF LEUKOCYTE BIOLOGY

TGF-  downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

(2011) C. A. Crane et al.   NEURO-ONCOLOGY

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

(2010) Raphaël Maréchal et al.   BMC CANCER

The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors

(2010) Carol M Lee et al.   BMC CANCER

IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA

(2010) Stephan Kloess et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

A Human NK Cell Activation/Inhibition Threshold Allows Small Changes in the Target Cell Surface Phenotype To Dramatically Alter Susceptibility to NK Cells

(2010) T. D. Holmes et al.   JOURNAL OF IMMUNOLOGY

IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion

(2010) Sabine Huenecke et al.   JOURNAL OF IMMUNOTHERAPY

Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells

(2009) C. Cerboni et al.   BLOOD

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies

(2009) M. Campoli et al.   CLINICAL CANCER RESEARCH

A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab

(2009) Kwang-Won Hong et al.   JOURNAL OF BIOTECHNOLOGY

Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck

(2009) William N William et al.   Nature clinical practice. Oncology

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells

(2008) Paolo Carrega et al.   CANCER

FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

(2008) Rodney J. Taylor et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis

(2008) Sabine Huenecke et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Tumor cell recognition by the NK cell activating receptor NKG2D

(2008) Yenan T. Bryceson et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients

(2008) Shigehiro Tamaki et al.   HUMAN IMMUNOLOGY